Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Changes Up R&D But Not Backing Down On Oncology

Executive Summary

The appointment of oncologist Thomas Lynch to succeed Francis Cuss as Chief Scientific Officer suggests the biopharma won’t be straying too far from its current focus on developing cancer drugs.

Advertisement

Related Content

Bristol's New Chief Scientific Officer Lists Oncology Priorities, But Little New
It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel